Proactive - Interviews for investors

In a notable shift in the cryptocurrency market, Bitcoin (BTC), the world’s leading digital currency, experienced a significant setback. This week, Bitcoin's price plunged by 5.8%, wiping out a week's gains and raising concerns among investors.

Despite this downturn, Bitcoin showed resilience, recovering slightly by 1.4% to $41,888. However, this volatility had a substantial impact on the futures market, where $130 million in long positions were lost in a single day, marking the largest loss in recent months.

The ripple effects of Bitcoin's fluctuation were felt across related stocks, notably Coinbase Global Inc., which saw a near 6% decrease. Meanwhile, Ethereum (ETH) also closed 5.4% lower. In contrast, the altcoin sector showed signs of growth, with Binance’s BNB token and the Layer-2 blockchain token Avalanche (AVAX) recording significant gains, suggesting a diversifying interest in cryptocurrencies beyond Bitcoin.

#ProactiveInvestors #Bitcoin #Cryptocurrency #Altcoins #BTC #Ethereum #ETH #BitcoinETF #CryptoMarket #Blockchain #BitcoinHalving #CryptoInvesting #DigitalCurrency #CryptoNews #FuturesMarket #CryptoStocks #Coinbase #Binance #Avalanche #AVAX #Solana #Cardano #Ripple #XRP #CryptoTrends #MarketVolatility #CryptoAnalysis #InvestmentTrends #FinancialMarkets #CryptoTrading #CryptoUpdate #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Greencoat UK Wind PLC (LSE:UKW) Investment co-Manager Stephen Lilly speaks to Thomas Warner from Proactive after the company announced it has completed the acquisition of a 49.9% interest in Kype Muir Extension wind farm from Banks Renewables.

Lilly provides more detail about this latest step in a long-term deal and says it has propelled Greencoat's capacity to over two gigawatts.

Lilly also addresses Greencoat's cautious capital allocation strategy, acknowledging the challenges in raising equity and the importance of judicious investment decisions. Despite opportunities for expansion, current market conditions limit their ability to acquire new assets. The company has prioritised shareholder value through strategies like buybacks and dividend increases, with the recent dividend being raised to 10 pence.

Furthermore, Lilly expresses frustration over the market's perceived undervaluation of Greencoat's return on investment. He stressed the significance of returns over yields, especially in a rising interest rate environment. Lilly believes the market has not fully appreciated the combined value of Greencoat's dividends and reinvestments but says Greencoat UK Wind is "well placed... so we're not unduly worried - we just have to be patient."

The interview also touched on personnel changes within Greencoat, specifically the transition of Laurence Fumagalli, a long-time colleague of Lilly. Matt Ridley, a familiar face in the UK wind sector and current Head of Private Markets at Schroders Greencoat, is set to succeed Fumagalli, ensuring continuity in the company's leadership.

#GreencoatUKWind #StephenLilly #RenewableEnergy #WindEnergy #InvestmentStrategy #SustainableInvesting #GreenEnergy #UKWindFarms #EnergySector #RenewableInvestment #WindPower #UKRenewables #EnergyFinance #WindFarmAcquisition #CorporateStrategy #EnergyTransition #GreencoatInvestments #CleanEnergy #EcoInvesting #UtilitySector

#ProactiveInvestors #wind #greenenergy #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Philipp Stratmann, CEO of Ocean Power Technologies joined Steve Darling from Proactive to to announce a significant development for the company. Ocean Power Technologies has secured a letter contract from a US-based prime contractor for the delivery of multiple maritime domain awareness buoys, with a strong emphasis on national security and intelligence.

Stratmann shared insights into this collaborative effort between OPT and the prime contractor, emphasizing the shared goal of providing multidomain marine solutions in support of US government agencies. OPT's PowerBuoy technology will serve as a cornerstone in enhancing surveillance capabilities both above and below the waterline, making a substantial contribution to maritime domain awareness initiatives.

The current contract enables OPT to advance the preparation of multiple Next Generation PowerBuoy systems, with the expectation of receiving further details in the future.

The integration of OPT's cutting-edge technology signifies a significant step forward in bolstering maritime surveillance efforts, ultimately enhancing security and safety within the maritime domain. This collaboration reinforces OPT's position as a key player in the development of innovative solutions that contribute to national security and intelligence efforts.

#proactiveinvestors #oceanpowertechnologiesinc #nyseamerican #optt

#RenewableEnergy #MaritimeTechnology #DefenseContracts #Innovation #GreenTech #CEOInterview #SustainableSolutions #CleanEnergy #TechnologyNews #USGovernment #SecurityContracts #BuoySystems #MaritimeAwareness #StrategicFocus #FutureTech #EnvironmentalImpact #CorporateAchievements #2024Plans #EnergyInnovation #SmartTechnology #BreakingNews #TechIndustry #ClimateSolutions #ShareholderValue

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Century Lithium CEO Bill Willoughby joined Steve Darling from Proactive to to provide an update on the company's ongoing efforts related to lithium extraction, including advancements in pilot plant testing and the progress of the Feasibility Study for the Clayton Valley Project.

Century Lithium's comprehensive Feasibility Study encompasses all aspects of the lithium extraction process, from shallow surface mining of lithium-bearing clay to the on-site production of battery-grade lithium carbonate. In line with their commitment to efficiency and optimization, the company has collaborated with its Feasibility Study team to revise and update estimates.

In response to the inherent volatility in the lithium market, Century Lithium is exploring a phased approach to full-scale production. This strategy aims to offer prospective investors and partners a lower-risk financing alternative. The company is actively working with its consultants to identify viable phases and establish associated schedules.

One particularly promising development arising from pilot plant testing is the significant surplus of sodium hydroxide generated as a by-product during the lithium extraction process. Given the Western United States' heavy reliance on imports for this essential chemical, Century Lithium recognizes the potential for revenue from the sale of sodium hydroxide. This by-product could serve as a valuable domestic supply of sodium hydroxide, catering to various industrial needs, including water treatment.

To properly evaluate these alternatives and incorporate the economic benefits of by-product sales, Century Lithium is conducting a market study, which will be seamlessly integrated into the overarching Feasibility Study.

In essence, Century Lithium's strategic approach to lithium extraction not only encompasses innovative and optimized processes but also emphasizes revenue diversification through the sale of valuable by-products. This multifaceted approach positions the company as a key player in the lithium market, capable of contributing to the domestic supply chain while mitigating financial risk.

#proactiveinvestors #centurylithiumcorp #tsxv #lce #otcqx #cydvf #mining #lithium

#LithiumMarket #PilotPlant #DLPProcess #RenewableEnergy #CleanTech #Sustainability #MiningIndustry #FeasibilityStudy #TechInnovation #EnergyTransition #GreenTech #ResourceDevelopment #CEOInterview #MarketAnalysis #SodiumHydroxide #2024Outlook #SupplyChain #InvestmentOpportunity #ElectricVehicles #BatteryTechnology #MiningUpdate #EcoFriendly #GreenEnergy #FutureTech#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

NuGen Medical Devices Chief Executive Officer Ian Heynen joined Steve Darling from Proactive to discuss his appointment and share some exciting news regarding the company's needle-free InsuJet injection device.

Heynen brings a wealth of experience to his role as CEO, with a strong track record in the med-tech industry. He has a history of leadership in technology-driven organizations, ranging from operational start-ups to turnaround situations and high-growth companies. Heynen's expertise includes managing P&Ls for both North American and international businesses, with multi-site divisions and gross revenues exceeding $600 million. He is known for driving growth through product innovation and international expansion in both startup and multinational firms.

In addition to his appointment, Heynen also shared a significant achievement for NuGen Medical Devices. The Mexican government has completed the registration of NuGen's needle-free InsuJet injection device as a medical device for sale throughout the country. Furthermore, NuGen has a distribution agreement in place with Science-Link, aiming to sell approximately 5,000 needle-free injectors in 2024.

Looking to 2024, Heynen outlined NuGen's plans for both geographical market expansion and a strategic shift towards collaborating with pharma companies and healthcare systems. The goal is to broaden the technology's recognition and accessibility, particularly in Canada, the US, the UK, and additional EU markets. The interview showcases NuGen's commitment to revolutionizing medical device technology and improving patient experiences worldwide.

#proactiveinvestors #nugenmedicaldevicesinc #tsxv #ngmd #diabetes #needlefree

#NeedleFreeTechnology, #InsulinDelivery, #HealthcareInnovation, #MedicalTech, #CEOInterview, #GlobalHealth, #PatientExperience, #HealthTechRevolution, #DiabetesCare, #MedicalDevices, #InnovationInTheClinic, #SelfAdministeredMedicine, #PainlessInjections, #FutureOfHealth, #MexicoHealthcare, #PharmaPartnerships, #MedicalBreakthrough, #CommunityHealth, #2024HealthGoals, #HealthcareAccess, #DigitalHealth, #WellnessTech, #HealthcareLeadership#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Cielo Waste Solutions CEO Ryan Jackson joined Steve Darling from Proactive to the company's innovative technology addressing waste-to-fuel, distinguishing it from biofuel production. Cielo focuses on waste streams, not food sources like corn or soy, creating biofuel with feedstocks such as wood waste and railway ties.

Jackson highlighted their exclusive deal with Expander Energy for project development, unveiling plans for six facilities in the next five years.Cielo strategically opts for multiple smaller facilities rather than one large one, driven by feedstock availability. The technology's sweet spot, producing 1500 to 2000 barrels per day, allows flexibility in facility placement, minimizing costs. The company primarily collaborates with the railway industry, addressing the disposal challenge of creosote-treated railway ties.Looking ahead to 2024, Jackson emphasized advancing projects through engineering and design stages, aiming for groundbreaking on at least two facilities.

Cielo recently announced a capital raise for specific projects, demonstrating their commitment to sustainable waste solutions.Stay tuned for Cielo Waste Solutions' progress as they drive innovation in waste-to-fuel technology.

#proactiveinvestors #cielowastesolutions #tsxv #

#CieloWasteSolutions #SustainableTech #BiofuelInnovation #RenewableEnergy #GreenTechnology #ProjectDevelopment #EnvironmentalSolutions #FeedstockTechnology #InnovationInWasteManagement #CleanEnergyFuture #Circulareconomy #ClimateAction #EcoFriendly #GreenProjects #BiofuelProduction #Project2024 #WasteTransformation #CarbonNeutral #SustainableBusiness #CleanTechLeadership #GreenInvesting #RenewableResources #ZeroWaste #FutureOfEnergy

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

MustGrow Biologics Chief Executive Officer Corey Giasson joined Steve Darling from Proactive to share news MustGrow Biologics has signed a collaboration agreement with Bayer that focuses on the soil applications of MustGrow's mustard-based biocontrol technologies across Europe, the Middle East, and Africa (EMEA). It's important to note that this collaboration excludes home and garden, turf, and ornamental applications.

Under this collaboration agreement, MustGrow Biologics is set to receive an initial upfront payment. Moreover, the company stands to gain additional payments tied to the achievement of specific business milestones. As a significant milestone, once commercial sales commence, MustGrow will also be entitled to receive fees from royalties and manufacturing sales.

The financial implications of this collaboration are substantial, with MustGrow anticipating that the combined value of upfront payments, milestone achievements, and Development Work could amount to an impressive sum ranging from USD $35 to $40 million over the course of several years. This projection does not even include the potential additional revenue from royalties and manufacturing sales.

This partnership between MustGrow Biologics and Bayer reflects the growing recognition of MustGrow's innovative and environmentally friendly biocontrol technologies, which have the potential to revolutionize agriculture and contribute to sustainable farming practices across the EMEA region. The collaboration marks a significant step forward for both companies, positioning them as key players in the global agriculture industry's ongoing quest for effective, sustainable, and eco-friendly solutions.

#proactiveinvestors #mustgrowbiologicscorp #tsxv #mgro #otcqb #mgrof #mustardseed

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

First Phosphate Corp CEO John Passalacqua joined Steve Darling from Proactive to share shared significant news with Steve Darling from Proactive. The company has signed a memorandum of understanding (MOU) with Ultion Technologies, based in Las Vegas, Nevada, for the procurement of lithium iron phosphate (LFP) and lithium iron manganese phosphate (LFMP) cathode active material.

Passalacqua provided insights into the scope of this MOU, revealing that the LFP technology covered by the agreement is already in production across two facilities. One facility boasts an impressive annual capacity of 10,000 tonnes, while the other can produce up to 50,000 tonnes annually. This extensive production capacity underscores the scale of the operation.

To put the potential market value of 50,000 tonnes of LFP cathode active material into perspective, Passalacqua highlighted that it could range from USD $625 million to USD $1.25 billion, based on recent market price ranges.

In addition to LFP, the MOU also encompasses LFMP technology, which is currently in development and being produced at a quantity of several tonnes per month.

These developments showcase the strategic importance of First Phosphate Corp's partnership with Ultion Technologies, positioning the company to capitalize on the burgeoning demand for lithium-based materials in the rapidly expanding battery and clean energy sectors. This agreement reflects the company's commitment to providing essential materials for sustainable and renewable energy solutions while contributing to the growth of the global lithium supply chain.

#proactiveinvestors #firstphosphatecorp #cse #phos #phosphate #pea #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

#OlteanTechnologies #CEOInterview #LFPBattery #TechnologyPartnership #StrategicExpansion #RenewableEnergy #BatteryInnovation #SpecialtyProducts #EnergyStorage #CleanTech #SustainableBusiness #TechCollaboration #CommercialScale #InnovationLeadership #IndustryInsights #RenewableFuture #GreenTechNews #CorporatePartnerships #DiversificationStrategy #FutureTechTrends #CleanEnergyRevolution #SustainableDevelopment #LFPApplications #TechRiskMitigation

OptionsDesk broker Alex Mitchell kicks off the new week by Thomas Warner from Proactive about what the glut of fresh economic news and data expected this week.

Mitchell says the week is packed with significant events, starting with the release of US CPI and PPI figures on Tuesday. This will be followed by the Federal Reserve's interest rate decision on Wednesday. The week continues with Thursday's retail sales and jobless claims data, along with the Bank of England and European Central Bank rate decisions.

Mitchell acknowledges that recent data releases have muddied predictions and made this week's data even more significant than usual. He says central banks are seeking evidence of a weakening labour market before considering rate reductions.

Mitchell says investors are particularly focused on Tuesday's CPI data, which could prove to be a key indicator. Additionally, he points out China's economic challenges, marked by deflation concerns and weak PMI data. This situation shifts investors' attention towards emerging markets like India.

The interview concludes with Mitchell underscoring the importance of the Federal Reserve's language in shaping market expectations. Investors will be keenly observing this week's developments to gauge future rate cuts and overall market direction.

#ProactiveInterview #AlexMitchell #Optionsdesk #FinancialAnalysis #CPI #PPI #FedRateDecision #EconomicData #USMarkets #Inflation #LaborMarket #NonFarmPayrolls #InterestRates #CentralBanks #EconomicIndicators #RetailSales #JoblessClaims #VRA #ECB #MarketTrends #ChinaEconomy #EmergingMarkets #IndiaEconomy #GlobalEconomics #InvestmentStrategies #EconomicForecast #MarketInsights #ProactiveInvestors #FTSE #interest #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief executive Dr Markku Jalkanen speaks to Thomas Warner from Proactive London after the clinical stage biopharmaceutical company announced "very positive" Phase 1 data from the ongoing BEXMAB study in myeloid malignancies.

The data is being presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition taking place until tomorrow, December 12, 2023, in San Diego, California, and virtually.

Jalkanen says the data reveals a promising response in patients, especially in inducing myeloid differentiation in Myelodysplastic Syndrome (MDS), a condition with limited treatment options. Typically, patients with this type of cancer have a life expectancy of around 24 months, making these results particularly significant.

Investors and shareholders have responded positively to this latest news, as the trial shows a response rate potentially 5 to 10 times higher than the current standard of care. Faron Pharmaceuticals is now preparing to advance to the next trial phases and is exploring potential partnerships.

Regarding the company's overall performance in 2023, Dr. Jalkanen expresses satisfaction with Faron's ability to maintain and even increase its pace, with promising data accumulating from ongoing trials and the initiation of new ones. The company is targeting a marketing approval application by 2025, staying on track with its previously set goals.

#FaronPharmaceuticals #LeukemiaTreatment #ClinicalTrials #MyeloidMalignancies #Glenavon #Hematology #ASHMeeting #MDS #PharmaceuticalIndustry #InvestorInsights #HealthcareInnovation #2023MedicalBreakthroughs #CancerResearch #MedicalAdvancements #HealthSectorNews #BiotechUpdates #MarkGalkin #PharmaCEOInterview #OncologyDevelopments #RegulatoryApproval #ProactiveInvestors #Faron #FARN #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews